Cholesterol biology · LDL receptor cycle · 5 drug modalities · Trial data · Oral vs injectable economics · Investment implications
Cross-Drug Comparison Caveats
Different patient populations, baseline LDL-C levels, background therapies, trial durations, and analysis methods across studies. Enlicitide Phase 3 data at 24 weeks; AZD0780 Phase 2b data at 12 weeks (shorter duration may understate full effect). Injectable mAb and siRNA data from approved labels. CVOT data available only for evolocumab (FOURIER) and alirocumab (ODYSSEY). No head-to-head trials between oral and injectable PCSK9 inhibitors exist.
Sources: NEJM, JACC, Circulation, Merck press releases, AstraZeneca press releases, FDA labels, ClinicalTrials.gov · Updated March 2026